Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE

Amarin Shares Slide After Public Offering Announcement

By Pharmaceutical Processing | July 9, 2013

U.S.-traded shares of Amarin Corp. PLC tumbled in premarket trading today, a day after the Irish drugmaker said it plans to sell 21.7 million American Depositary Shares in an underwritten public offering.

Amarin said it would sell the shares at market prices, and it gave the banks running the offering an option to buy an additional 3.3 million shares to cover excess demand. The company had about 150 million shares outstanding at the end of the first quarter. That total could grow to more than 175 million if the option is exercised in full.

Amarin said it will use proceeds from its offering to continue the commercial launch of Vascepa, its treatment for patients with high triglyceride levels.

Vascepa is a prescription form of fish oil designed to lower triglycerides, a type of fat in the bloodstream. The company started selling the drug in the United States in January for use with severely high levels of triglycerides. It also is seeking approval from the U.S. Food and Drug Administration to market Vascepa as a treatment for patients with high triglyceride levels who also are taking a statin therapy to control their cholesterol.

The FDA is expected to decide on that additional use by December.

Amarin also plans to use offering proceeds to prepare for the launch of Vascepa for that additional use.

Shares of Amarin fell 8.3 percent, or 51 cents, to $5.66 in premarket trading Tuesday. The stock still hasn’t recovered from a slump that started last December, when Amarin said it would hire its own sales force as it prepared for Vascepa’s launch. That disappointed investors who were hoping Amarin would be sold to a larger drug company.

The stock price topped $12 before that announcement.

 

Related Articles Read More >

This is a photo of the Fujifilm Diosynth Biotechnologies plant under construction in Holly Springs, North Carolina.
Fujifilm, Regeneron ink $3B U.S. manufacturing agreement
This is the logo of Johnson & Johnson.
J&J breaks ground on $2B manufacturing facility in North Carolina
sherwin-williams-pharma-facility (1)
Sherwin-Williams expands flooring solutions for pharma facilities
PHARMAP 2025: Pharma leaders converge in Berlin for fifth anniversary summit
“ppw
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news, technologies, and developments in Pharmaceutical Processing.

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Pharmaceutical Processing World
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Drug Discovery & Development
  • DeviceTalks
  • MassDevice
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • Medical Design Sourcing
  • Medtech100 Index
  • R&D 100 Awards

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Pharmaceutical Processing World

  • Home
  • Regulatory
    • Recalls
  • Pharmaceutical Processing
  • Facility
  • Supply Chain
  • Equipment and Materials
  • Contract Manufacturing
  • Advertise
  • SUBSCRIBE